younger than 70 years of age, who harbored primary supratentorial GBMs involving the hemisphere(s). The patients were treated at Kumamoto University Hospital and its affiliated hospitals between April 1990 and March 2001. There were 26 men ranging in age from 23 to 69 years (median 54 years) and 20 women ranging from 17 to 69 years (median 51 years). Written informed consent was obtained from all patients and/or family members before the patients were entered into the study.
Clinical details, including the KPS score at the time of diagnosis, were recorded. All patients underwent surgical removal or biopsy sampling of their tumor, and the diagnosis of GBM was histologically confirmed according to World Health Organization criteria. 29 To determine the extent of resection, we performed early postoperative Gd-DTPAenhanced MR imaging. Resection was classified based on MR imaging as follows: gross-total, no residual lesions could be detected; subtotal, less than 10% of the original tumor mass remained; and partial, more than 10% of the mass remained postoperatively. Subtotal and partial resections were subsumed into the subtotal resection group.
All patients received postoperative adjuvant therapy. A dose of 45 to 50 Gy was administered to the high intensity area plus a 2-cm margin demonstrated on T 2 -weighted MR images; a boost to a total of 55 to 65 Gy was administered to the Gd-DTPA-enhanced area plus a 2-cm margin. Concomitant with radiotherapy, all patients received chemotherapy consisting of nimustine hydrochloride (ACNU) as a single agent or in combination with another agent(s), including procarbazine, vincristine, and interferon. After initial postoperative therapy, all patients were reexamined. The KPS score, tumor recurrence or regrowth, onset of clinical deterioration, and death were recorded. The survival time was measured as the time from the date of the initial surgery to the date of death. Progression-free survival time was measured from the date of the initial surgery to the onset of clinical deterioration or radiologically confirmed tumor recurrence.
Tumor Samples
Tumor samples were available from all patients. Tumor tissues were frozen immediately after removal and stored at Ϫ80˚C until the isolation of genomic DNA was performed. Other tumor tissues were placed in 10% formalin and submitted for histopathological examination.
Analysis of p16 for Homozygous Deletions
We used multiplex PCR for the analysis of p16 homozygous deletion. 4, 6, 24, 31, 39, 43, 50, 69 Genomic DNA from the frozen tumors was isolated by using proteinase K digestion and phenolchloroform extraction. The oligonucleotide primer sequences were 5Ј-ACAAGCTTCCTTTCCGTCAT-3Ј (sense) and 5Ј-GCGCACGTCCAGCCGCGCCCCGG-3Ј (antisense) for p16 exon 2 and primers 5Ј-ATTTCTGCC-TGGAGACAGTGG-3Ј (sense) and 5Ј-AGGCCTTGG-GAGCCTCAGG-3Ј (antisense) for STS reference on the long arm of chromosome 9 (9qSTS). 5, 64, 65 The PCR amplification was performed using a programmable thermal cycler (MJ Research, Boston, MA) in 25-l reaction volumes, including 150 to 200 ng genomic DNA, 20 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl 2 , 200 M deoxynucleoside triphosphates, 0.19-M primers for p16, 0.17-M primers for 9qSTS, 1.25 U Taq polymerase, and 5% dimethyl sulfoxide. After initial 3-minute denaturation at 95˚C, the annealing temperature was gradually decreased from 62˚C to 55˚C for two cycles each at 62˚C, 60˚C, and 59˚C, three cycles each at 58˚C, 57˚C, and 56˚C, and 13 cycles at 55˚C (28 total cycles). Each cycle was at 95˚C for 1 minute, annealing for 1 minute, and at 72˚C for 1 minute. A final extension step of 72˚C for 5 minutes was added. The total of 28 cycles was found to extend the linear range under these PCR conditions (data not shown). After PCR, 5 l of the reaction product was separated by electrophoresis on a 2% agarose gel and stained with 0.5 g/ml ethidium bromide under ultraviolet illumination. The resulting images were then density scanned. Band intensities for the areas corresponding to the amplimers of p16 and 9qSTS were determined using the 1.62 image program (Wayne Rasband Analytics; National Institutes of Health, Bethesda, MD) and the intensity ratio of p16/9qSTS was calculated. 47 
The MIB-1 Labeling Index
Immunostaining of the surgical specimens with MIB-1 was performed in all cases. Sections (6 m) were cut from paraffin-embedded tissues, mounted on glass slides, and dried. Immunostaining was performed using the avidinbiotin-peroxidase complex method described by Hsu, et al. 20 After routine deparaffinization, rehydration, and blocking of the endogenous peroxidase activity, the antigen was retrieved as previously described. 7, 62 Slide-mounted sections were incubated in a 0.01-mM sodium citrate retrieval buffer (pH 6) and then microwaved for 10 minutes at maximum power in a 700-W microwave oven. Using a 1: 50 dilution, sections were incubated overnight at 4˚C in MIB-1 monoclonal antibody (Immunotech S.A., Marseille, France). Antigen-antibody complexes were detected via the 3,3Ј-diaminobenzidine/H 2 O 2 reaction, which rendered Ki-67-immunopositive nuclei a dark brown color. Slides were lightly counterstained with hematoxylin, dehydrated, cleared, and mounted. Cells were considered positive for Ki-67 when unequivocal diffuse or dotlike brown nuclear staining could be identified. A minimum of 1000 cells within at least 10 adjacent fields were examined, beginning with the area of greatest immunopositivity. 40 Counting was performed by an experienced observer who was blinded to the data in this study. Stromal cell staining involving cytoplasmic positivity was excluded from the counting process. The MIB-1 LI in each case was calculated as the number of positive cells divided by the total number of examined cells in all fields inspected.
Statistical Analysis
We used the t-test to examine the possible correlation between patient age and the incidence of homozygous deletion of p16 and between the MIB-1 LI and the incidence of homozygous deletion of p16. Actuarial survival curves were generated using the Kaplan-Meier method. The logrank test was used to estimate differences between survival curves. Cox proportional hazard regression analysis was performed for multivariate analysis. The results of the regression analysis were adjusted for age (Յ 55 compared with Ͼ 55 years), preoperative KPS score (Ն 70 compared with Ͻ 70), extent of tumor resection (gross total, subtotal, biopsy), and MIB-1 LI (Ն 20 compared with Ͻ 20%) as previously described. 28, 30, 67 A probability value of less than 0.05 was considered statistically significant.
Results

Detection of p16 Homozygous Deletions by Multiplex PCR
To examine the validity of the multiplex PCR method for the detection of homozygous deletions of the p16 gene in tissue samples, titration experiments were performed using serial mixtures of normal human leukocyte DNA and DNA from a U251-MG human glioma cell line (Fig. 1) . The U251-MG cell line has the p16 homozygous deletion and no 9q abnormality. 4, 18 Titration experiments were repeated eight times and a standard curve was obtained (Fig.  2) . Homozygous deletion of p16 in the clinical tissue samples was determined according to the slightly modified method of Mochizuki, et al. 39 Briefly, because histological examination revealed that tumor samples contained less than 20% nontumor cells, tumor tissues with a p16/9qSTS ratio less than 0.46 were judged to contain a homozygous deletion. We reasoned that less than 20% of total DNA was made up of normal DNA (confidence level, 95%) based on the p16/9qSTS ratio of 20% normal DNA (0.343 Ϯ 2 standard deviations [0.121]). Figure 3 shows examples of multiplex PCR results in five cases.
Clinical Characteristics
Preoperative KPS scores ranged from 50 to 100 (median 80). Of the 46 patients, 15 underwent gross-total resection of their tumor, 26 subtotal resection, and in five patients a biopsy procedure was performed. By the time this analysis was conducted (July 24, 2001), 28 (61%) of the 46 patients had died of uncontrolled tumor; the remaining 18 patients survived for a median period of 7.6 months (3.3 months-7.21 years) after surgery. Clinical characteristics and prognostic factors are presented in Table 1 .
Homozygous Deletion of the p16 Gene
As shown in Table 1 , 14 (30.4%) of 46 patients had the deletion. The incidence was almost the same in both sexes: eight (30.8%) of 26 men and six (30.0%) of 20 women. There was no correlation between p16 deletion and age (p = 0.8646, t-test) or p16 deletion and MIB-1 LI (p = 0.8563, t-test).
The median survival duration for patients with and without the homozygous deletion was 0.84 and 1.87 years, respectively; the difference was not statistically significant (p = 0.1269, log-rank test; Fig. 4 ). The median survival of male patients with and without the deletion was 0.75 and 1.34 years, respectively; there was a statistically significant difference between these two groups (p = 0.0030, log-rank test). On the other hand, the deletion did not affect the survival duration for women; it was 1.82 years in those with and 1.98 years in those without the deletion (p = 0.8175, log-rank test).
Progression-free survival data were available in 43 (24 male, 19 female) patients. The median progression-free survival duration of patients with and without the deletion was 0.28 and 0.55 years, respectively; the difference was not statistically significant (p = 0.0977, log-rank test; Fig. 5 ). Among men with and without the deletion, the difference in median progression-free survival duration (0.27 and 0.55 years, respectively) was statistically significant (p = 0.0092, log-rank test). This was not the case in women (0.28 compared with 0.5 years; p = 0.7959, log-rank test).
Our statistical analyses suggest that in men with GBM, the p16 homozygous deletion is associated with both median survival and median progression-free survival. To assess the association of survival duration with multiple clinical characteristics, we performed multivariate analysis. As shown in Table 2 , the overall survival duration of men was significantly correlated with homozygous deletion of the p16 gene. The overall survival time of women was not associated with the deletion; these results are consistent with the data presented in Fig. 4C . In men, multivariate analysis revealed a correlation between the presence or absence of the deletion and progression-free survival duration (Table 3). Another significant prognostic factor was the patient age.
Discussion
We investigated whether homozygous deletion of the p16 tumor suppressor gene is associated with prognosis in patients with GBM. To make the patient cohort as uniform as possible, we selected patients with supratentorial GBM who were treated with surgery and postoperative radiotherapy and chemotherapy. We excluded patients older than 70 years of age because in these individuals chemotherapy is contraindicated.
Multiplex PCR is most widely used to detect p16 homozygous deletions in clinical samples because this method is simple, fast, and reliable. [4] [5] [6] 39, 43, 48, 64, 69 Perry, et al., 50 reported that in glioma tissue samples, the results of multiplex PCR were highly concordant with data obtained by fluorescence in situ hybridization and comparative genomic hybridization. Therefore, we used multiplex PCR in our study of the possible correlation between p16 homozygous deletions and the prognosis in patients with GBM.
The prognostic value of p16 abrogation in GBM remains controversial because data from most previous studies have failed to demonstrate an association between p16 abrogation and clinical outcome. 42 , 44 James, et al., 24 who analyzed homozygous deletions of the p16 gene in 135 glioma samples by using multiplex PCR, found no significant association with survival in 60 patients with Grade 4 tumors. Alleyne, et al., 1 performed Western blot analysis and compared progression-free survival between patients with and without p16 protein expression; they found no significant difference. Kraus, et al., 31 compared two age-and sexmatched groups of patients with GBMs and found that the frequency of p16 homozygous deletions was not significantly different between patients with shorter and longer postoperative time to tumor progression. Their findings also suggested that in patients with GBM, the presence or absence of the deletion was of no prognostic significance for overall patient survival. Puduvalli, et al., 52 examined p16 protein expression in 130 GBMs by using immunohistochemical methods and found no significant correlation between immunoreactivity and patient survival. In a series of 77 high-grade astrocytomas, Kirla, et al., 28 used univariate and multivariate analyses to examine the association of the expression of p16, p21, and p53 with patient survival and the clinical and proliferative characteristics of the tumor. Their parameters included patient age, tumor histology, extent of surgery, and Ki-67 LI. They found that p16 immunonegativity and Ki-67 LI were independent indicators of a poor prognosis. Although the reasons for these divergent findings remain unclear, the results may be affected by the methods used for the detection of homozygous deletions and the statistical analyses.
Our multiplex PCR assays revealed that homozygous deletion of the p16 gene was associated with shorter survival in men, but not in women with GBMs, suggesting a sex difference. In addition, men with the deletion had the shortest median overall survival duration and the shortest median progression-free survival time. Authors of several epidemiological studies documented a lower risk for GBM in female populations. 3, 13, 32, 37, 68 Although most investigators have not been able to identify sex as a prognostic factor, 9 some claim that women have a better prognosis. 12, 26, 36, 46, 53, 56 The possibility of hormonal involvement has been suggested. 26, 53 In their population-based case-control study, Schlehofer, et al., 57 demonstrated that menopause is significantly associated with the development of glioma, indicating a role of female hormones. In animal models, estrogen appears to confer a survival advantage and to play a role in the lower incidence of GBM. 35, 51 Furthermore, the possibility cannot be ruled out that in patients with GBM, sex hormones or sex differences, that is, differences in the susceptibility of X and Y chromosomes to tumorigenesis, play a role in both pathogenesis and prognosis. 37 of p16 was too small to draw firm conclusions regarding differences in survival between men and women, a larger study will disclose whether such differences exist.
The frequency of homozygous deletions of p16 in our study (30.4%) was lower than the 33 to 74% reported by others. 4, 11, 17, 25, 41, 59, 64, 69 To our knowledge, there are four reports in which Japanese patients 39, 48, 61, 63 were analyzed; in three of those multiplex PCR was used to detect the deletions. The reported frequency of homozygous deletions of p16 detected by this method was 17.1 to 46.2%. Mochizuki, et al., 39 noted a lower frequency in Japanese than in caucasian patients. The frequency of homozygous deletions of the p16 gene in our study (30.4%) falls within the range reported in the other four studies undertaken in Japan.
We did not examine hypermethylation of the 5Ј CpG island or mutation of the p16 gene; however, these abrogations have been reported to be rare in gliomas. 8, 14, 19, 33, 34, 38, 58 In our study, homozygous deletion of the p16 gene was associated with prognosis. This is presumably because the homozygous deletion is the most effective means of inactivating the INK4a-ARF locus where three tumor suppressor genes, p16, p15, and p14ARF, are located, resulting in abrogation of both Rb and p53 pathways. 16, 21 A systematic investigation is needed of the components of these pathways in relation to the prognosis of patients with GBM. 22 Although we do not have enough data on anaplastic astrocytomas, the significance of the p16 homozygous deletion in these tumors will be made clear by the study of large populations. Systematic large-scale studies will provide more information regarding various factors affecting the prognosis and response to adjuvant therapy in patients with tumors of the nervous system and will facilitate the development of better management strategies.
Conclusions
Our results suggest that homozygous deletion of the p16 gene is an unfavorable prognostic factor in men but not in women with GBM. 
